Pharmacogenomics and Psychiatric Nursing.

Area of Science:

• Pharmacogenomics
• Mental Health
• Clinical Pharmacy

Background:

• Mental illness treatment often relies on trial-and-error, with variable therapeutic success.
• Pharmacogenomics offers personalized approaches by examining gene-drug interactions and individual responses.
• Understanding genetic influences is crucial for optimizing psychotropic medication efficacy and safety.

Purpose of the Study:

• To investigate the impact of pharmacogenomic testing on the management of mental health medications.
• To evaluate changes in medication regimens and adverse drug reactions post-pharmacogenomic testing.
• To assess the utility of genetic testing in guiding psychotropic pharmacotherapy.

Main Methods:

• Retrospective chart review of patients at an outpatient mental health facility.
• Comparison of medication history, adverse drug reactions, and pharmacogenomic data for six months pre- and post-testing.
• Analysis of genetic variations in cytochrome enzymes CYP2D6 and CYP2C19.

Main Results:

• High incidence of genetic variations: 82% in CYP2D6 and 64% in CYP2C19.
• All patients (91% on Medicaid/Medicare) had their drug regimens modified post-testing.
• All patients reported fewer adverse side effects after treatment adjustments based on pharmacogenomic findings.

Conclusions:

• Pharmacogenomic testing demonstrates significant utility in optimizing mental health medication management.
• Personalized pharmacotherapy guided by genetic insights can reduce adverse drug reactions in psychiatric care.
• Further research is warranted to explore the benefits of pharmacogenomic testing in vulnerable mental health populations.